৳ 700/unit
Pack: ৳ 700
৳ 700/unit
Pack: ৳ 700
At a glance
Ibandronic Acid is used for the treatment and prevention of osteoporosis, especially in postmenopausal women and men.
Indications
- Treatment of osteoporosis in women (especially postmenopausal)
- Prevention of osteoporosis in women (especially postmenopausal)
- Prevention and treatment of osteoporosis in men
Pharmacology
Ibandronic acid is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. Its action on bone tissue is based on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. It inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Dosage
Adult Dose (Oral):
- Treatment of osteoporosis: 150 mg film-coated tablet once monthly (on the same date each month)
- Take 60 minutes before first food or drink of the day on empty stomach
- Swallow tablet whole with a full glass of plain water (180-240 ml)
- Take while standing or sitting upright
- Do not lie down for 60 minutes after taking
- Do not chew or suck the tablet
Missed Dose: If remembered, take the next morning (if next scheduled dose is not within 7 days); if within 7 days, wait until next dose; do not take two 150 mg tablets within the same week.
Child Dose: Safety and efficacy not established in patients less than 18 years
Side effects
Common Side Effects:
- Headache
- Musculoskeletal (bone, muscle or joint) pain
- Dyspepsia
- Heartburn
- Diarrhea
- Abdominal pain
- Nausea
- Dizziness
- Back pain
- Flatulence
- Constipation
Serious: Severe bone, joint and/or muscle pain; osteonecrosis of the jaw; esophagitis, esophageal ulcers or erosions; hypocalcemia
Use in pregnancy
Use in Pregnancy: Should not be used during pregnancy; no clinical experience in pregnant women; no direct fetal toxic or teratogenic effects in animal studies.
Precautions & warnings
Precautions:
- Treat hypocalcemia and other disturbances of bone and mineral metabolism before starting therapy
- Caution in patients with active upper gastrointestinal problems (Barrett's esophagus, dysphagia, gastritis, duodenitis, ulcers)
- Discontinue and seek medical attention if esophageal irritation symptoms develop
- Risk factors for osteonecrosis of the jaw: cancer, chemotherapy, radiotherapy, corticosteroids, pre-existing dental disease
- Not recommended in severe renal impairment (CrCl <30 ml/min)
Overdose effects
Overdose: Oral overdose may result in upper gastrointestinal adverse events (upset stomach, heartburn, esophagitis, gastritis, ulcer); milk or antacids should be given to bind ibandronic acid; do not induce vomiting due to risk of esophageal irritation; patient should remain fully upright.
Storage conditions
Keep below 30°C temperature, away from light & moisture; keep out of reach of children.